Please use this identifier to cite or link to this item:
Title: Bevacizumab in colorectal cancer: current and future directions.
Austin Authors: Yeung, Yvonne;Tebbutt, Niall C 
Affiliation: Ludwig Institute for Cancer Research, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 31-Oct-2012
Publication information: Expert Review of Anticancer Therapy 2012; 12(10): 1263-73
Abstract: Bevacizumab is a humanized monoclonal antibody to VEGF-A, an important therapeutic target through its proangiogenic effects on a variety of tumors. Bevacizumab has demonstrated clinically meaningful benefit in conjunction with chemotherapy for patients with metastatic colorectal cancer as well as other tumor types. Bevacizumab is a well-tolerated therapy with regard to toxicity, in keeping with its biological vascular effect. In this era of personalized medicine, current Phase II and III trials are further defining its role at various stages of metastatic disease and the optimal sequencing with cytotoxic and other targeted agents to achieve further improvements in patient outcome. Translational research for biomarker discovery and validation and further study into mechanisms of resistance are essential for future development and sustained benefit with this class of therapeutic agents.
Gov't Doc #: 23113577
DOI: 10.1586/era.12.104
Type: Journal Article
Subjects: Angiogenesis Inhibitors.adverse effects.pharmacokinetics.pharmacology.therapeutic use
Antibodies, Monoclonal, Humanized.adverse effects.pharmacokinetics.pharmacology.therapeutic use
Clinical Trials as Topic
Colorectal Neoplasms.blood supply.drug therapy.metabolism
Drug Resistance, Neoplasm
Randomized Controlled Trials as Topic
Tumor Markers, Biological.metabolism
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 9, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.